Oppenheimer analyst Michael Wiederhorn raised his price target for UnitedHealth to $300 from $295 following quarterly results. The analyst believes the company remains an industry leader across its various business lines, and has both a diversified and insulated business model that boasts promising growth prospects. He reiterates an Outperform rating on the shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here